| Product Type | Impurity Standards |
| CAT. No. | MRL-M50001 |
| CAS. No. | NA |
| Mol. Formula | C6H12N2O5 |
| Mol. Weight | 192.17 |
| Chemical Name | (2R,3S,4R,5S)-2-(hydroxymethyl)-1-nitrosopiperidine-3,4,5-triol |
| HSN Code | 38229010 |
| Country of Origin | India |
| Stock Status | Custom Synthesis |
Nitrosamines can be formed through various chemical processes, including the reaction between nitrites and secondary amines in certain conditions. It is a N-Nitroso of secondary amine present in Migalastat. Nitrosamines are part of a broader class of compounds known as N-nitroso compounds. Migalastat is a medication used for the treatment of Fabry disease, a rare genetic disorder characterized by the buildup of a fatty substance called globotriaosylceramide in various organs and tissues. Its chemical structure includes a bicyclic ring system. Migalastat is classified as a pharmacological chaperone, working by stabilizing and increasing the activity of certain mutant forms of the alpha-galactosidase A enzyme. This enzyme deficiency is the underlying cause of Fabry disease. By facilitating the proper folding and trafficking of the enzyme, migalastat helps enhance its activity, reducing the accumulation of globotriaosylceramide and mitigating symptoms associated with Fabry disease. Migalastat is taken orally and is designed to treat specific genetic mutations associated with Fabry disease, offering a targeted therapeutic approach for individuals with this rare disorder. As with any medication, its use and dosage should be directed by healthcare professionals based on individual patient characteristics and genetic profile. Buy high quality N-Nitroso Migalastat from Molsyns Research. Molsyns Research is one of the leading manufacturer and exporter of N-Nitroso Migalastat.